caa a22 4500 463255674 CHVBK 20180405153354.0 cr unu---uuuuu 170326e20070901xx s 000 0 eng 10.1007/s00277-007-0320-8 doi (NATIONALLICENCE)springer-10.1007/s00277-007-0320-8 Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients [Elektronische Daten] [J. Li, L. Wang, Y. Shen, Z. Xia, Y. Chen, Q. Chen, Y. Chen, X. Zeng, J. You, Y. Qian, Z. Shen] The objective of this study is to evaluate the long-term efficacy and safety of rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in Chinese patients with newly diagnosed diffuse large B cell lymphoma (DLBCL). The study comprised a retrospective analysis of patients treated at a single center. Patients received four to six infusions of rituximab (375mg/m2 per dose) on day1 of each cycle of CHOP chemotherapy. CHOP was initiated on day3 of each cycle; cycles were repeated at 21-day intervals. A total of 82 patients with a median age of 45years (range 18-76years) was included. The overall response (OR) and complete response (CR) rates were 90.2 and 70.7%, respectively. The estimated 5-year progression-free survival (PFS) and overall survival (OS) rates were 56.4 ± 8.3% and 74.1 ± 7.4%, respectively. Patients with International Prognostic Index (IPI) scores ≤2 had significantly higher OR, CR, PFS, and OS rates (p = 0.01, p = 0.02, p = 0.01, p < 0.001, respectively) compared with patients with IPI scores >2. The hematologic toxicity was mild. Five patients with a history of chronic hepatitis B experienced a reactivation of viral hepatitis. The rituximab-CHOP combination was effective and well tolerated in Chinese patients with newly diagnosed DLBCL. Springer-Verlag, 2007 Non-Hodgkin's lymphoma nationallicence DLBCL nationallicence Rituximab nationallicence CHOP nationallicence Survival nationallicence Li J. Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University (SSMU), Shanghai, China aut Wang L. Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University (SSMU), Shanghai, China aut Shen Y. Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University (SSMU), Shanghai, China aut Xia Z. Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University (SSMU), Shanghai, China aut Chen Y. Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University (SSMU), Shanghai, China aut Chen Q. Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University (SSMU), Shanghai, China aut Zeng X. Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University (SSMU), Shanghai, China aut You J. Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University (SSMU), Shanghai, China aut Qian Y. Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University (SSMU), Shanghai, China aut Shen Z. Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University (SSMU), Shanghai, China aut Annals of Hematology Springer-Verlag 86/9(2007-09-01), 639-645 0939-5555 86:9<639 2007 86 277 https://doi.org/10.1007/s00277-007-0320-8 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00277-007-0320-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Li J. Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University (SSMU), Shanghai, China aut NATIONALLICENCE 700 1- Wang L. Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University (SSMU), Shanghai, China aut NATIONALLICENCE 700 1- Shen Y. Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University (SSMU), Shanghai, China aut NATIONALLICENCE 700 1- Xia Z. Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University (SSMU), Shanghai, China aut NATIONALLICENCE 700 1- Chen Y. Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University (SSMU), Shanghai, China aut NATIONALLICENCE 700 1- Chen Q. Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University (SSMU), Shanghai, China aut NATIONALLICENCE 700 1- Zeng X. Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University (SSMU), Shanghai, China aut NATIONALLICENCE 700 1- You J. Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University (SSMU), Shanghai, China aut NATIONALLICENCE 700 1- Qian Y. Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University (SSMU), Shanghai, China aut NATIONALLICENCE 700 1- Shen Z. Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University (SSMU), Shanghai, China aut NATIONALLICENCE 773 0- Annals of Hematology Springer-Verlag 86/9(2007-09-01), 639-645 0939-5555 86:9<639 2007 86 277 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer